 SP848 will be open to subjects who have participated in other LCM pediatric clinical studies in epilepsy and will also be open to up to 100 subjects enrolling directly into SP848. Permissible LCM doses in SP848 are between 2-12 mgkgday oral solution syrup or the corresponding tablet dose up to a maximum dose of 600 mgday. 